Welcome back to another edition of Endpoints Weekly. Thanks to everyone who came out to our AI Day event this week in New ...
Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a ...
Eli Lilly's neuroscience president Carole Ho expressed interest in ibogaine R&D at NYC's Psychedelic Healthcare Forum, ...
China's Commerce Ministry proposes restricting export of cell/gene therapy, siRNA, and pathogen tech, while preserving drug ...
Research shows 952K+ US clinicians made 271M queries to AI tool OpenEvidence from Jan 2024–June 2026. But there are concerns ...
More former Genentech leaders are finding a new home. Lélia Delamarre posted on LinkedIn that she’s leading R&D at ARCH-backed cancer biotech Medici Therapeutics, one of this year’s Endpoints 11 ...
NorthStar/Quarkmed, Lonza/Qurient CDK7 deal, Triastek/J&J 3D printing pact, Scinai's $5.1M deal & HydRegen's $8M Series A led ...
Paul Stoffels’ new Armed Cell Therapeutics buys Lakefront’s (ex-Galapagos) preclinical CAR-T work for $9M upfront, $230M in ...
OMass has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the ...
Sanofi's new R&D chief said on Wednesday Western drugmakers cannot ignore China's accelerating innovation and should consider ...
FDA launches Rare Disease Framework Initiative to tailor reviews by disease, with a stakeholder meeting set for Oct. 28.
Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results